What is the approximate market price of a bottle of Ocriplasmin?

Ocriplasmin (Ocriplasmin) is an enzyme preparation used to treat vitreo-macular traction syndrome (VMT) and related epiretinal membrane (ERM). Since it was approved for marketing by the US FDA in October 2012, it has been used in overseas clinical practice for many years. Its unique feature is that it enzymatically cleaves the adhesion structure between the vitreous body and the macula, including fibronectin and laminin, so that the vitreous body naturally peels off, thereby reducing the traction pressure on the macula and improving the morphology of the macula and central vision function. Compared with traditional vitrectomy (PPV), Oakplasmin provides a non-surgical, minimally invasive treatment approach, especially suitable for patients with early or moderate maculopathy, as well as those who are elderly or have underlying diseases who are not suitable for surgery.

Regarding the market price, Oak Plasmin has not yet been approved for marketing in China, so patients cannot purchase it through formal channels in China, nor can it be included in medical insurance reimbursement items. If patients need to use the drug, they must rely on overseas drug purchase channels or participate in international clinical trials. This not only increases the cost of treatment, but also places higher requirements on drug transportation, storage and use. In overseas markets, the specifications of Oak Plasmin are usually 2.5mg/ml, and the price per bottle is about US$4,000, which is equivalent to about 30,000 to 35,000 yuan in RMB. Due to the special properties of its enzyme preparation and the complex production process, there are currently no generic drugs or cheap substitutes, so the cost of the drug is high. For ordinary patients, such cost is obviously a huge burden, and it also limits its large-scale clinical popularization.

In addition to the high price, the use of Oak plasmin also needs to consider the storage conditions of the drug, and its activity is greatly affected by temperature and transportation conditions. Cold chain transportation is usually required, and preparation and injection must be carried out in strict accordance with the instructions before use to ensure efficacy and safety. When clinicians choose to use Oakplasmin, they will consider the severity of the patient's maculopathy, vitreous traction and previous treatment history, and evaluate the patient's financial affordability and potential benefits to decide whether to use this treatment option.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html